Vitamin therapy in schizophrenia

Israel Journal of Psychiatry and Related Sciences

Volumn 45, Issue 1, 2008, Pages 3-10

  Hoffer, Leonard John ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 45549109167     PISSN: 03337308     EISSN: 26172402     Source Type: Journal    
DOI: None     Document Type: Article

References (82)

1. Cummings JL, Mega MS. Psychosis, delusions, and schizophrenia. Neuropsychiatry and behavioral neuroscience. New York: Oxford University, 2003: pp. 172-186.
2. Perkins DO, Gu H, Boteva K, Lieberman JA. Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: A critical review and meta-analysis. Am J Psychiatry 2005;162:1785-1804.
3. Stroup TS, Alves WM, Hamer RM, Lieberman JA. Clinical trials for antipsychotic drugs: Design conventions, dilemmas and innovations. Nat Rev Drug Discov 2006;5:133-146.
4. Harrow M, Jobe TH. Factors involved in outcome and recovery in schizophrenia patients not on anti-psychotic medications: A 15-year multifollow-up study. J Nervous Mental Disease 2007;195:406-414.
5. Johnstone EC, Macmillan JF, Crow TJ. The occurrence of organic disease of possible or probable aetiological significance in a population of 268 cases of first episode schizophrenia. Psychol Med 1987;17:371-379.
6. Perry TL, Hansen S, Tischler B, Richards FM, Sokol M. Unrecognized adult phenylketonuria. Implications for obstetrics and psychiatry. N Engl J Med 1973;289:395-398.
7. Kalaydjian AE, Eaton W, Cascella N, Fasano A. The gluten connection: The association between schizophrenia and celiac disease. Acta Psychiatr Scand 2006;113:82-90.
8. De Santis A, Addolorato G, Romito A, Caputo S, Giordano A, Gambassi G, Tarante C, Manna R, Gasbarrini G. Schizophrenic symptoms and SPECT abnormalities in a coeliac patient: Regression after a gluten-free diet. J Intern Med 1997;242:421-423.
9. Pauling L. Orthomolecular psychiatry. Science 1968;160:265-271.
10. Hoffer LJ. Testing the homocysteine hypothesis in end-stage renal disease: Problems and a possible solution. Kidney Int 2006;69:1507-1510.
11. Popper CW. Do vitamins or minerals (apart from lithium) have mood-stabilizing effects? J Clin Psychiatry 2001;62:933-935.
12. Gesch CB, Hammond SM, Hampson SE, Eves A, Crowder MJ. Influence of supplementary vitamins, minerals and essential fatty acids on the antisocial behaviour of young adult prisoners. Randomised, placebo-controlled trial. Br J Psychiatry 2002;181:22-28.
13. Ames BN, Elson-Schwab I, Silver EA. High-dose vitamin therapy stimulates variant enzymes with decreased coenzyme binding affinity (increased K(m)): Relevance to genetic disease and polymorphisms. Am J Clin Nutr 2002;75:616-658.
14. Bedalov A, Simon JA. Neuroscience. NAD to the rescue. Science 2004;305:954-955.
15. Klaidman L, Morales M, Kem S, Yang J, Chang ML, Adams JD, Jr. Nicotinamide offers multiple protective mechanisms in stroke as a precursor for NAD+, as a PARP inhibitor and by partial restoration of mitochondrial function. Pharmacology 2003;69:150-157.
16. Blom W, van den Berg GB, Huijmans JGM, Sanders-Woudstra JAR. Successful nicotinamide treatment in an autosomal dominant behavioral and psychiatric disorder. J Inter Metab Dis 1985;8 (Suppl. 2):107-108.
17. Coppen A, Bailey J. Enhancement of the antidepressant action of fluoxetine by folic acid: A randomised, placebo controlled trial. J Affect Disord 2000;60:121-130.
18. Bottiglieri T, Laundy M, Crellin R, Toone BK, Carney MW, Reynolds EH. Homocysteine, folate, methylation, and monoamine metabolism in depression. J Neurol Neurosurg Psychiatry 2000;69:228-232.
19. Levine J, Stahl Z, Sela BA, Gavendo S, Ruderman V, Belmaker RH. Elevated homocysteine levels in young male patients with schizophrenia. Am J Psychiatry 2002;159:1790-1792.
20. Applebaum J, Shimon H, Sela BA, Belmaker RH, Levine J. Homocysteine levels in newly admitted schizophrenic patients. J Psychiatr Res 2004;38:413-416.
21. Levine J, Sela BA, Osher Y, Belmaker RH. High homocysteine serum levels in young male schizophrenia and bipolar patients and in an animal model. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:1181-1191.
22. Regland B. Schizophrenia and single-carbon metabolism. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:1124-1132.
23. Goff DC, Bottiglieri T, Arning E, et al. Folate, homocysteine, and negative symptoms in schizophrenia. Am J Psychiatry 2004;161:1705-1708.
24. Muntjewerff JW, Blom HJ. Aberrant folate status in schizophrenic patients: What is the evidence? Prog Neuropsychopharmacol Biol Psychiatry 2005;29:1133-1139.
25. Hankey GJ, Eikelboom JW. Homocysteine and stroke. Lancet 2005;365:194-196.
26. Gilbody S, Lewis S, Lightfoot T. Methylenetetrahydrofolate reductase (MTHFR) genetic polymorphisms and psychiatric disorders: A HuGE review. Am J Epidemiol 2007;165:1-13.
27. Freeman JM, Finkelstein JD, Mudd SH. Folate-responsive homocystinuria and "schizophrenia": A defect in methylation due to deficient 5,10-methylenetetrahyofolate reductase activity. N Engl J Med 1975;292:491-496.
28. Godfrey PS, Toone BK, Carney MWP, Flynn TG, Bottiglieri T, Laundy M, Chanarin I, Reynolds EH. Enhancement of recovery from psychiatric illness by methylfolate. Lancet 1990;336:392-395.
29. Procter A. Enhancement of recovery from psychiatric illness by methylfolate. Br J Psychiatry 1991;159:271-272.
30. Kinsman RA, Hood J. Some behavioral effects of ascorbic acid deficiency. Am J Clin Nutr 1971;24:455-464.
31. Levine M, Conry-Cantilena C, Wang Y, Welch RW, Washko PW, Dhariwal KR, Park JB, Lazarev A, Graumlich JF, King J, Cantilena LR. Vitamin C pharmacokinetics in healthy volunteers: Evidence for a recommended dietary allowance. Proc Natl Acad Sci USA 1996;93:3704-3709.
32. Smythies JR. The role of ascorbate in brain: Therapeutic implications. J Royal Soc Med 1996;89:241.
33. Smythies JR. Oxidative reactions and schizophrenia: A review-discussion. Schizophr Res 1997;24:357-364.
34. Rebec GV. Ascorbate: An antioxidant neuroprotectant and extracellular neuromodulator. In: Connor JR, editor. Metals and oxidative damage in neurological disorders. New York: Plenum, 1997: pp.149-173.
35. Panel on Dietary Antioxidants and Related Compounds, Subcommittees on Upper Reference Levels of Nutrients and Interpretation and Uses of Dietary Reference Intakes, Standing Committee on the Scientific Evaluation of Dietary Reference Intakes. Dietary reference intakes: Vitamin C, vitamin E, selenium, and beta-carotene and other carotenoids. Washington, D.C.: National Academy, 2000.
36. Smythies J. Redox aspects of signaling by catecholamines and their metabolites. Antioxid Redox Signal 2000;2:575-583.
37. Milner G. Ascorbic acid in chronic psychiatric patients: A controlled trial. Br J Psychiatry 1963;109:294-299.
38. Schorah CJ, Morgan DB, Hullin RP. Plasma vitamin C concentrations in patients in a psychiatric hospital. Human Nutr Clin Nutr 1983;37:447-452.
39. Tucker BW, Tolbert BM, Halver JE, Balaban M. Brain ascorbate depletion as a response to stress. Int J Vitam Nutr Res 1987;57:289-295.
40. Reddy R, Keshavan M, Yao JK. Reduced plasma antioxidants in first-episode patients with schizophrenia. Schizophr Res 2003;62:205-212.
41. Rumelin A, Humbert T, Luhker O, Drescher A, Fauth U. Metabolic clearance of the antioxidant ascorbic acid in surgical patients. J Surg Res 2005;129:46-51.
42. Brody S. High-dose ascorbic acid increases intercourse frequency and improves mood: A randomized controlled clinical trial. Biol Psychiatry 2002;52:371-374.
43. Brody S, Preut R, Schommer K, Schurmeyer TH. A randomized controlled trial of high dose ascorbic acid for reduction of blood pressure, cortisol, and subjective responses to psychological stress. Psychopharmacology 2002;159:319-324.
44. Dakhale GN, Khanzode SD, Khanzode SS, Saoji A. Supplementation of vitamin C with atypical antipsychotics reduces oxidative stress and improves the outcome of schizophrenia. Psychopharmacology 2005;182:494-498.
45. Beauclair L, Vinogradov S, Riney SJ, Csernansky JG, Hollister LE. An adjunctive role for ascorbic acid in the treatment of schizophrenia? J Clin Psychopharmacol 1987;7:282-283.
46. Sandyk R, Kanofsky JD. Vitamin C in the treatment of schizophrenia. Int J Neurosci 1993;68:67-71.
47. Hoffer A, Osmond H, Callbeck MJ, Kahan I. Treatment of schizophrenia with nicotinic acid and nicotinamide. J Clin Exp Psychopathol 1957;18:131-158.
48. Hoffer A. Niacin therapy in schizophrenia. Springfield, 111.: Charles C. Thomas, 1962.
49. Osmond H, Hoffer A. Massive niacin treatment in schizophrenia: Review of a nine-year study. Lancet 1962;1:316-320.
50. Hoffer A. Nicotinic acid: An adjunct in the treatment of schizophrenia. Am J Psychiatry 1963;120:171-173.
51. Hoffer A, Osmond H. Treatment of schizophrenia with nicotinic acid: A ten-year follow-up. Acta Psychiatr Scand 1964;40:171-189.
52. O'Reilly PO. Nicotinic acid therapy and the chronic schizophrenic. Dis Nerv Syst 1955;16:67-72.
53. Hoffer A. Megavitamin B-3 therapy for schizophrenia. Can Psychiatr Assoc J 1971;16:499-504.
54. Hoffer A. LSD-induced psychosis and vitamin B 3. Am J Psychiatry 1972;128:1155.
55. Hoffer A, Osmond H. The hallucinogens. New York: Academic Press, 1967.
56. Osmond H, Hoffer A. A comprehensive theory of schizophrenia. Int J Neuropsychiatry 1966;2:302-309.
57. Smythies J. Endogenous neurotoxins relevant to schizophrenia. J Royal Soc Med 1996;89:679-680.
58. Baez S, Segura-Aguilar J, Widersten M, Johansson AS, Mannervik B. Glutathione transferases catalyse the detoxication of oxidized metabolites (o-quinones) of catecholamines and may serve as an antioxidant system preventing degenerative cellular processes. Biochem J 1997;324:25-28.
59. Smythies J. The adrenochrome hypothesis in schizophrenia revisited. Neurotox Res 2002;4:147-150.
60. Horrobin DE Schizophrenia: A biochemical disorder? Biomedicine 1980;32:54-55.
61. Carlson LA. Nicotinic acid: The broad-spectrum lipid drug. A 50th anniversary review. J Intern Med 2005;258:94-114.
62. Pfeiffer CC, Ward J, El-Meligi M, Cott A. The schizophrenias, yours and mine. New York: Pyramid Books, 1970.
63. Osmond H. The background to the niacin treatment. In: Hawkins D, Pauling L, editors. Orthomolecular psychiatry: Treatment of schizophrenia. San Francisco: W.H.Freeman, 1973: pp.194-201.
64. Hawkins D, Pauling L. Orthomolecular psychiatry: Treatment of schizophrenia. San Francisco: W. H. Freeman and Company, 1973.
65. Lipton MA, Ban TA, Kane FJ, Levine J, Mosher LR, Wittenborn R. Task Force Report 7. Megavitamin and Orthomolecular therapy in psychiatry. Washington, D.C.: American Psychiatric Association, 1973.
66. Wittenborn JR, Weber ES, Brown M. Niacin in the long-term treatment of schizophrenia. Arch Gen Psychiatry 1973;28:308-315.
67. Wittenborn JR. A search for responders to niacin supplementation. Arch Gen Psychiatry 1974;31:547-552.
68. Ban TA, Lehman HE. Nicotinic acid in the treatment of schizophrenias. Can Psychiatr Assoc J 1975;20:103-112.
69. Hoffer J. Megavitamin treatment of schizophrenia. Can Psychiatr Assoc J 1975;20:492-495.
70. Hoffer J. Megavitamin treatment of schizophrenia. Can Psychiatr Assoc J 1976;21:133-134.
71. Brown WT. Megavitamin and orthomolecular therapy of schizophrenia. Can Psychiatr Assoc J 1975;20:97-100.
72. Messamore E, Hoffman WF, Janowsky A. The niacin skin flush abnormality in schizophrenia: A quantitative dose-response study. Schizophr Res 2003;62:251-258.
73. Smesny S, Berger G, Rosburg T, Riemann S, Riehemann S, McGorry P, Sauer H. Potential use of the topical niacin skin test in early psychosis - a combined approach using optical reflection spectroscopy and a descriptive rating scale. J Psychiatr Res 2003;37: 237-247.
74. Smesny S, Rosburg T, Riemann S, Baur K, Rudolph N, Berger G, Sauer H. Impaired niacin sensitivity in acute first-episode but not in multi-episode schizophrenia. Prostaglandins Leukot Essent Fatty Acids 2005;72:393-402.
75. Horrobin DF. The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia. Schizophr Res 1998;30:193-208.
76. Peet M. New strategies for the treatment of schizophrenia: Omega-3. In: Peet M, Glen I, Horrobin DF, editors. Phospholipid spectrum disorder in psychiatry. Lancashire: Marius, 1999: pp. 189-192.
77. Berger GE, Smesny S, Amminger GP. Bioactive lipids in schizophrenia. Int Rev Psychiatry 2006;18:85-98.
78. Lai E, De Lepeleire I, Crumley TM, Liu F, Wenning LA, Michiels N, Vets E, O'Neill G, Wagner JA, Gottesdiener K. Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D2 receptor subtype 1. Clin Pharmacol Ther 2007;81:849-857.
79. Horrobin DF. Effective clinical innovation: An ethical imperative. Lancet 2002;359:1857-1858.
80. Antman K, Lagakos S, Drazen J. Designing and funding clinical trials of novel therapies. N Engl J Med 2001;344:762-763.
81. Lasagna L. The impact of scientific models on clinical psychopharmacology: A pharmacologist's view. Semin Psychiatry 1972;4:271-282.
82. Cotzias GC, Papavasiliou PS, Gellene R. Modification of Parkinsonism - chronic treatment with L-dopa. N Engl J Med 1969;280:337-345.